13 completed, 2 terminated. 15 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 13, Terminated 2 |
| Phase 2 | 3 | Completed 3 |
Follow Cilengitide: new trials by email Literature Review of Cilengitide trials Research Report on Cilengitide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics in Subjects With Renal Impairment cilengitide 2000mg, cilengitide 1000mg, cilengitide > 1000mg and up to 2000mg - Renal Impairment | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 32 | 2012-01-01 | 2014-02-04 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery Cilengitide, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2016-03-15 |
| Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Cilengitide dose escalation, Cilengitide, Concomitant radiotherapy - Diffuse Intrinsic Pontine Glioma | Phase 1 | Completed | Centre Oscar Lambret | 32 | 2010-09-06 | 2026-03-16 |
| Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 47 | 2010-03-01 | 2015-04-15 |
| Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer cilengitide, radiochemotherapy - Locally Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | Institut Claudius Regaud | 14 | 2010-03-01 | 2026-04-14 |
| Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme Cilengitide, Clinical Observation, Laboratory Biomarker Analysis - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 41 | 2009-12-01 | 2015-04-28 |
| Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer cilengitide, pharmacological study, radiation therapy - Brain and Central Nervous System Tumors, Lung Cancer | Phase 1 | Completed | Universitätsmedizin Mannheim | 19 | 2008-12-01 | 2024-05-10 |
| Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Cilengitide 2000 mg once weekly, Cilengitide 2000 mg twice weekly, Cetuximab - Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 184 | 2008-10-01 | 2014-04-30 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme cilengitide, temozolomide, radiation therapy - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 112 | 2005-04-01 | 2016-02-25 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma cilengitide - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2003-12-01 | 2013-01-24 |
| Cilengitide in Treating Children With Refractory Primary Brain Tumors cilengitide, laboratory biomarker analysis - Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2003-07-01 | 2013-09-30 |
| EMD 121974 in Treating Patients With Advanced Solid Tumors cilengitide, pharmacological study, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2001-05-01 | 2013-01-25 |
| EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma cilengitide - Sarcoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2000-09-01 | 2013-06-03 |
| EMD 121974 in Treating Patients With Progressive or Recurrent Glioma cilengitide - Brain and Central Nervous System Tumors | Phase 1 / Phase 2 | Completed | New Approaches to Brain Tumor Therapy Consortium | 2000-09-01 | 2013-06-24 | |
| EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer cilengitide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | Indiana University | 40 | 1999-12-01 | 2014-09-17 |
Brain Neoplasms (4) · Glioblastoma (4) · Gliosarcoma (4) · Lymphoma, Follicular (3) · Astrocytoma (2) · Burkitt Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Hodgkin Disease (2) · Immunoblastic Lymphadenopathy (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2)
National Cancer Institute (NCI) (8) · Merck KGaA, Darmstadt, Germany (2) · Centre Oscar Lambret (1) · Indiana University (1) · Institut Claudius Regaud (1) · New Approaches to Brain Tumor Therapy Consortium (1) · Universitätsmedizin Mannheim (1)
United States (10) · France (3) · Germany (3) · Austria (1) · Belgium (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1) · Switzerland (1)
Andreas Becker, MD MSc (1) · Barbara J. Klencke, MD (1) · Christian Manegold, MD (1) · Elizabeth Gerstner (1) · Jan Vermorken, MD, PhD (1) · Julian Molina (1) · Louis B. Nabors, MD (1) · Louis Nabors, MD (1) · Michael Maitland (1) · Michael S. Gordon, MD (1) · Michele Basche (1) · Samir Undevia (1) · Tobey MacDonald (1)
PMID 17470857, PMID 22517399, PMID 24567516, PMID 29221762
2008 (1), 2009 (1), P30CA014599 (1), P30CA015083 (1), U01CA062475 (1), U01CA069852 (1), U01CA069912 (1), U01CA081457 (1), U01CA099176 (1), U01CA137443 (1)